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GENERAL COMMENTS
The manuscript entitled " The cost-effectiveness of a care manager collaborative care programme for patients with depression in primary care -economic evaluation of a pragmatic randomised controlled study " contains a cost-effectiveness analysis of a collaborative care intervention in primary care. The objective of the study are very important and relevant, as this was the first study to evaluate the cost effectiveness of a care manager program for the treatment of depression in Swedish primary care. However, the faulty study methods, i.e., the method of handling missing data, the breach of intention-to-treat (exclusion of patients due to missing information, the analysis of costeffectiveness and the missing sensitivity analysis are sufficient reasons for rejection of the manuscript publication. However, in order to give the authors the opportunity to revise the manuscript fundamentally, here are some major issues of the manuscript to be dealt with. The abstract and the citation style need to be revised and important text sections need to be provided with related references. The ICER was calculated based on change in MADRS-S. However, the BDI-II was also used for measurement of depressive symptoms. There need to be additional analyses using the BDI-II as effect measure. Furthermore, neither the ICER per change in MADRS-S nor change in BDI-II is meaningful for decision-makers. Analyses need to be based on response, remission and/or depression-free days, as they are effect measures more comprehensible. Furthermore, calculation of QALYs has not been described in the methods sufficiently. LOCF as method for handling missing data is inadequate, as it is incapable of providing consistent estimates, even under missing completely at random and the standard error of the estimates will become too small. It would be more convenient to use multiple imputation as method for handling missing data. However, at least additional analyses using pairwise/listwise deletion and mean imputation as alternative methods for handling missing data to outline the uncertainty of the imputation should be carried out and presented. For analysis of sampling uncertainty, the NMB has been used. However, in the calculation of NMB, no control for baseline characteristics, baseline costs and effects or the cluster effect has been presented. In the presentation of the results, there are further shortcomings. First, total costs have been reported. However, those costs are not meaningful for interpretation of the cost-effectiveness of the intervention. Second, baseline costs and intervention costs are missing. Second, negative ICERs should not be reported, as the interpretation of them is not definitive. Last, the authors used a WTP-threshold of 10.000€ per reduced point on MADRS-S, which seems to be very high. In the limitations, the short follow-up, the missing intention-to-treatanalysis and all those methodological weaknesses need to be discussed more adequate. Generalizability of the results need to be reformulated way more restricted, as the sample of which the results have been drawn are not representative for a greater population group at all. Last, based on these major shortcomings of the study, the conclusion should be drawn very cautious. -In terms of costs you can use primarily euros, both in the text and in the tables. In this way, understanding is facilitated to the international reader.
VERSION 1 -AUTHOR RESPONSE
Our reply: Yes, we have now provided everything in the text, and in (the new) Table 3 in Euros. We wanted to keep the new Table 2 (with all the cost items listed) in SEK, since this will make it able for other researchers in the future to translate the costs to other currencies using the (future) relevant exchange rates.
-In the text, report the ICERs, from the perspective of society as well as from the perspective of the health system. Certainly, they are stated in the tables, but this is a main outcome that must be emphasized.
Our reply: Yes, we have now included this in the text and tables.
-Complete the analysis by applying the techniques to measure the uncertainty of the estimates of ICER and 'willingness to pay' from the point of view of the healthcare system (often this perspective is the most determinant for the healthcare manager that must decide the implementation of a health intervention)
Our reply: This is now done, please see the new Figure 1 and Figure 2 showing the CE-plane and CEAC using both perspectives.
-Have the authors explored if it is possible to convert MADRS scores to DFD (depression free days)? If this were possible, it would facilitate the comparison of their results with those of other published studies.
Our reply: Yes, we thank the reviewer for this suggestion. We now present the results in terms of QALYs and DFDs instead (based on the MADRS-S scores).
-Specify clearly in the legends of the figures that they correspond to the analysis from a societal perspective.
Our reply: Fixed, although now we clearly specify that we have included both perspectives in the figures.
Reviewer: 2 Reviewer Name: Thomas Grochtdreis Institution and Country: University Medical Center Hamburg-Eppendorf, Germany Competing Interests: None
The ICER was calculated based on change in MADRS-S. However, the BDI-II was also used for measurement of depressive symptoms. There need to be additional analyses using the BDI-II as effect measure. Furthermore, neither the ICER per change in MADRS-S nor change in BDI-II is meaningful for decision-makers. Analyses need to be based on response, remission and/or depression-free days, as they are effect measures more comprehensible. Furthermore, calculation of QALYs has not been described in the methods sufficiently.
Our reply: We do not quite understand the suggestion to amend the results with cost per BDI-II reduction, at the same time as the reviewer states that cost per MADRS-S reduction and BDI-II reduction is not meaningful (i.e. the suggestions are slightly conflicting). However, we have, in line with the suggestion from the other reviewer as well, included an analysis in terms of the cost per (gained) depression-free days (together with the cost per QALY results). We have also included a description that QALYs were calculated by assuming linear interpolation between the measurement points.
LOCF as method for handling missing data is inadequate, as it is incapable of providing consistent estimates, even under missing completely at random and the standard error of the estimates will become too small. It would be more convenient to use multiple imputation as method for handling missing data. However, at least additional analyses using pairwise/listwise deletion and mean imputation as alternative methods for handling missing data to outline the uncertainty of the imputation should be carried out and presented.
Our reply: We have now performed the analysis with mean imputation based on linear regressions and clearly specified this in the paper. It had very minor effects on the results.
For analysis of sampling uncertainty, the NMB has been used. However, in the calculation of NMB, no control for baseline characteristics, baseline costs and effects or the cluster effect has been presented.
Our reply: It is not obvious, assuming successful randomization, why this should be included. As seen in Table 1 , there is no evidence that the randomization was contaminated. The estimate should be unbiased, although precision may be better if including covariates (and we do not have any data on baseline costs; if the reviewer refers to costs incurred in some time period before the randomization). Further, we have not specified specific baseline covariates to adjust for in the pre-analysis plan for this study, which we feel is another strong reason not to start, in a post-hoc manner, to include different covariates here.
However, as suggested, we have redone the analyses using a mixed model where the patients are directly modelled as nested within the primary care centers. This had some very small effects on the standard errors, but still p<0.001 for QALYs and depression free days. We thank the referee for the suggestion on covariates in general, since it may clearly be important to adjust for baseline utility (which we unfortunately missed in the previous version). This is now done, which reduced the treatment effectiveness to some degree (from around 0.024 QALYs to 0.017 QALYs). Main results though, are very similar (cost-effectiveness).
In the presentation of the results, there are further shortcomings. First, total costs have been reported. However, those costs are not meaningful for interpretation of the cost-effectiveness of the intervention. Second, negative ICERs should not be reported, as the interpretation of them is not definitive.
Our reply: We have changed
Our reply: All negative ICERs in the south-east quadrant, so actually this is not really a problem. But yes, we take the larger point, and now we do not report any negative ICERs.
Last, the authors used a WTP-threshold of 10.000€ per reduced point on MADRS-S, which seems to be very high.
Our reply: See above, based on the recommendations from both reviewers we changed the effectiveness measures to QALYs together with DFDs.
In the limitations, the short follow-up, the missing intention-to-treat-analysis and all those methodological weaknesses need to be discussed more adequate.
Our reply: The short-follow up time was mentioned already in the previous version. We have now discussed this slightly more, indicating that this is likely to under-estimate the costeffectiveness of the programme (since the health benefits were maintained at 6 months follow up). We are not sure what the reviewer mean by the missing intention-to-treat analysis; we do perform an ITT (here everyone is a complier given that randomization was carried out at the PCC level), although we as noted have 35 patients that were lost after randomization. Regarding the latter, we have now included a discussion of this and note that out of around 10 individual covariates only age was significantly related to missing after randomization (and the magnitude for age was also small).
Generalizability of the results need to be reformulated way more restricted, as the sample of which the results have been drawn are not representative for a greater population group at all. Last, based on these major shortcomings of the study, the conclusion should be drawn very cautious.
Our reply: We strongly disagree with the statement that "…are not representative for a greater population group at all". That would, in our mind, be an extremely conservative outlook on the external validity of the study. Since it is a pragmatic randomized effectiveness trial, it is (as far as RCTs go) the best possible starting-point for external validity. That being said, losing 35 out of 376 patients is of course unfortunate, although in comparison to many other similar studies we would say is actually quite a good number. We believe the current discussion is fair and balanced given the strengths and weakness with the study. 
VERSION 2 -REVIEW REVIEWER
GENERAL COMMENTS
Thank you for giving me the opportinity to comment on the revised manuscript entiteld "The cost -effectiveness of a care manager collaborative care programme for patients with depression in primary care -economic evaluation of a pragmatic randomised controlled study". The authors diligently anwered to the reviewers' comments concering their first draft of the manuscript. However, major issues are still not addressed. Inpatient care costs and costs for nursing care seem that they have not been collected/estimated. This major limitation needs to be addressed. Please show costs and cost differences between intervention group and control group in table 2. The total costs in table 2 and 3 are not identical. Furthermore, please add standard errors/confidence intervals to table 3. Before using mean imputation for handling missing data, incomplete cases were still deleted. Already under the assumption of missing completely at random, this approach is waste of data and unethical. Under the assumption of missing at random, the results of the study even might be biased.
In the current version of the manuscript, still sensitivity analyses are missing. Please show how using BDI-II instead of MADRS-S for calculation of the DFD changes your main results. Please show the difference of LOCF and mean imputation as imputation method in an additional analysis. Please include baseline MADRS-scores/EQ-5D scores to your NMB regression. The non-presence of baseline costs (meaning costs incurred e.g. half a year before treatment) is a major limitation that should be addressed. Please refer in your methods section to the mixed model that has been used. The results are not generalizable and representative for Swedish primary care. They might be generalizable to newly diagnosed mild to moderately depressed primary care patients in Västra Götalan and Dalarna.
